Could a soy supplement help your liver? new trial investigates
NCT ID NCT07623044
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tests whether daidzein, a natural compound found in soy, can improve liver tissue health in adults with metabolic dysfunction-associated steatotic liver disease (MASLD). 44 participants scheduled for gallbladder surgery will take daidzein capsules or receive standard care for 28 days before surgery. Researchers will then compare liver tissue samples to see if daidzein reduces fat, inflammation, and cell damage.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
daidzein (a natural compound from soy)
What this could lead to
If it works, this could point toward a simple, natural supplement to help control liver damage in people with MASLD.
What could go wrong
This is a small, early-phase trial with only 44 people, so results may not apply widely. It is also very short-term (28 days), so any benefits might be temporary or not lead to long-term improvement.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METABOLIC DYSFUNCTION ASSOCIATED STEATOTIC LIVER DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••